

CCS					
-1.0 (-3.5, 1.5)	CTL				
-0.4 (-2.1, 1.2)	0.5 (-1.9, 2.9)	HA			
-1.9 (-5.7, 1.9)	-0.9 (-5.1, 3.3)	-1.5 (-4.9, 2.0)	HA+PRP		
-1.6 (-3.2, 0.1)	-0.6 (-3.2, 2.1)	-1.1 (-2.9, 0.6)	0.3 (-3.4, 4.2)	NS	
-1.9 (-4.4, 0.4)	-1.0 (-4.1, 2.0)	-1.5 (-3.3, 0.2)	-0.1 (-3.5, 3.4)	-0.4 (-2.9, 2.0)	PRP

CCS				
0.45 (-2.00, 2.93)	HA			
0.12 (-4.1, 5.1)	-0.32 (-3.97, 3.89)	HA + PRP		
0.07 (-11.3, 7.10)	-0.36 (-11.56, 6.14)	-0.16 (-11.90, 7.27)	Placebo	
0.90 (-1.9, 4.58)	0.47 (-1.27, 2.97)	0.86 (-3.02, 4.61)	0.92 (-5.80, 12.40)	PRP

Supplementary Figure 4. League tables showing the results of the network meta-analyses comparing the reduction in VAS pain scores (95% credible intervals) for 2-4 months (A) and 6 month (B) follow-up.